ALXO News and Press, ALX Oncology Holdings Inc. From 10/04/23

2023-10-04 09:59:33 ET More on Health Care Select Sector SPDR September Labor Report Preview: Full Employment To Infinity Stagflation Playbook: Short Tech (QQQ/ARKK) And Long Healthcare (XLV) Citi turns cautious on pharmaceuticals and biotech BofA Securities:...

2023-10-04 08:14:01 ET More on ALX Oncology, Ocean Biomedical, Inc., etc. ALX Oncology Holdings: Gilead News Creates A New Risk Ocean Biomedical: Some New Targets, No Clinical Data. Not For Me Biggest stock movers today: NextEra Energy Partners, WeWork, ALX Oncology,...

2023-10-03 12:12:51 ET DENVER, Colo., Oct 3, 2023 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual midday volume; ALX Oncology Holdings (NASDAQ: ALXO), POINT Biopharma Global (NASDAQ: PNT), SciSparc (NASD...

2023-10-03 11:15:29 ET Shares of ALX Oncology (NASDAQ: ALXO) had skyrocketed by 53% as of 11:10 a.m. ET on Tuesday. The huge gain came after the immuno-oncology company announced positive interim results from a phase 2 study evaluating evorpacept in combination with trastuzuma, Cyra...

ALX Oncology Holdings Inc. (NASDAQ: ALXO) is one today's most active stocks by volume. So far today, approximately 25.04M shares of ALX Oncology Holdings Inc. have been exchanged, as compared to an average 30-day volume of 161.12k shares. ALX Oncology Holdings Inc., a clinical-stage immuno-onc...

2023-10-03 09:59:26 ET DENVER, Colo., Oct 3, 2023 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual volume; ALX Oncology Holdings (NASDAQ: ALXO), POINT Biopharma Global (NASDAQ: PNT), SciSparc (NASDAQ: SPRC), ODDITY Tec...

2023-10-03 08:41:53 ET Gainers: Alx Oncology ( ALXO ) +116% . Vericity  ( VERY ) +95% Strengthens Individual Insurance Presence in the United States with the Acquisition of Vericity. POINT Biopharma Global  ( PNT ) +85% to acquire Point ...

2023-10-03 08:13:54 ET (24/7 MARKET NEWS) – ALX Oncology Holdings Inc., (NASDAQ: ALXO) published, this morning, positive prespecified interim Phase 2 data from its ASPEN-06 clinical trial, a randomized multi-center international study evaluating evorpacept, the Company’s CD47 ...

2023-10-03 06:56:20 ET More on ALX Oncology ALX Oncology Holdings: Gilead News Creates A New Risk ALX Oncology surges Phase 2 data for gastric cancer therapy Biggest stock movers today: ALX Oncology Holdings, Sibanye Stillwater and more Seeking Alpha’s...

-- Evorpacept is the first CD47 blocker to show activity in a global randomized study in solid tumors -- Interim efficacy results showed the confirmed overall response rate for evorpacept combination treatment was 52% compared to 22% for control treatment -- Company to host ...